NEPH

Nephros, Inc. (NEPH) 10Y Growth Potential Analysis (2026)

Invetso Score: 5.5/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 5.8 (Moderate)

R&D intensity of 7.0% of revenue supports product refresh and pipeline renewal, but it is below high-growth peers with heavier reinvestment.

Negative net debt and very strong interest coverage preserve financing flexibility, enabling selective growth investment more easily than leveraged peers.

ROIC of 12.7% indicates capital can still be redeployed profitably, though the absence of multi-year revenue CAGR data limits proof of compounding.

Current valuation implies the market expects some growth durability, yet it does not by itself demonstrate stronger revenue scaling than peers.

Market Tailwinds

Score:

The company appears to operate with durable demand characteristics, but no filing-based evidence here shows a structurally faster end-market than direct peers.

Lack of disclosed segment concentration metrics limits proof of exposure to the highest-growth niches, reducing confidence in above-peer market expansion.

Compared with top-tier compounders, the available data show steadier rather than accelerating demand support for long-term revenue growth.

Without post-2025 filing evidence, the tailwind case remains credible but not strong enough to justify a premium growth profile.

Scalability Expansion

Score:

Low reported capex intensity suggests the model can scale without heavy asset buildout, which is more flexible than capital-intensive peers.

Strong cash generation capacity and low leverage improve reinvestment optionality, supporting expansion if demand opportunities emerge.

The 186.7-day cash conversion cycle signals working-capital drag, which can slow compounding relative to peers with faster cash turns.

No disclosed multi-year revenue growth series or segment expansion data limits evidence that the business can sustain above-peer scaling.

Constraints Limitations

Score:

The long cash conversion cycle ties up capital in operations, constraining reinvestment speed versus peers with tighter working-capital discipline.

Missing five-year revenue, EPS, and FCF CAGR data reduces visibility into whether growth is repeatable and scalable across cycles.

R&D spend is meaningful but not especially high, which may limit the pace of differentiated product expansion versus more aggressive innovators.

The available metrics do not show a structural growth impairment, but they also do not evidence a clearly superior scaling engine.

Overall Score

Score:

NEPH shows a viable but not clearly superior long-term growth profile, with balance-sheet flexibility and modest reinvestment capacity offset by working-capital drag and limited proof of above-peer scaling.

Score Driver: Working Capital Drag

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Nephros, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →